The global single-photon emission computed tomography market size was estimated to be USD 2.19 billion in 2023 and is expected to reach USD 3.14 billion by 2034 with a CAGR of 3.34% during the forecast period 2024-2034. The market will expand as a result of the following factors such as rising awareness and diagnostic needs, increasing incidence of chronic diseases, integration of SPECT with other imaging modalities, technological innovations and research initiatives, and rising rates of chronic disease.
The overall performance of SPECT systems is improved by ongoing developments in imaging technology, including as increases in detector sensitivity, image resolution, and data processing. Modern technology enhances the value and accuracy of SPECT as a diagnostic tool. For instance, Siemens Healthineers received FDA certification in April 2023 for their SPECT-CT system, the Biograph mCT Flow, which is intended for cardiac perfusion imaging.
By type, the Tc-99m segment accounted for the highest revenue-grossing segment in the global single-photon emission computed tomography market in 2023 owing to the widespread availability, cost-effectiveness, and well-established clinical efficacy of technetium-99m radiotracers. For instance, in July 2023, GE Healthcare unveiled the Discovery NM 750i SPECT system, which has better workflow capabilities and improved image reconstruction algorithms. Additionally, the Ga-67 segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for gallium-67 radiotracers in oncology applications. Gallium-67's unique properties, such as its affinity for tumor tissues and inflammatory lesions, make it particularly valuable for diagnostic imaging in cancer patients.
By application, the cardiology segment accounted for the highest revenue-grossing segment in the global single-photon emission computed tomography market in 2023 owing to the increasing prevalence of cardiovascular diseases worldwide and the critical role of SPECT in myocardial perfusion imaging. For instance, in May 2023, Philips Healthcare received CE Mark approval for the Philips Vereos PET/CT system, therefore increasing its SPECT imaging capabilities in Europe. Additionally, the oncology segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing global incidence of cancer and the expanding applications of Single-Photon Emission Computed Tomography (SPECT) in oncological imaging.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global single-photon emission computed tomography market in 2023 owing to the pivotal role of SPECT in routine clinical diagnostics and comprehensive patient care within hospital settings. For instance, Toshiba Corporation and the University of Tokyo Hospital announced a partnership in August 2023 to develop AI-powered image processing tools for SPECT exams. Additionally, the diagnostic imaging centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards outsourcing medical imaging services and the rising demand for specialized diagnostic facilities.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high adoption of advanced medical technologies, and a significant focus on research and development in the field of medical imaging. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing healthcare investments, rising prevalence of chronic diseases, and a growing awareness and adoption of advanced medical imaging technologies, including Single-Photon Emission Computed Tomography (SPECT). For instance, Hitachi, Ltd. introduced the Elucix SPECT system in July 2023, which is intended for effective and superior cardiac and bone imaging.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The overall performance of SPECT systems is improved by ongoing developments in imaging technology, including as increases in detector sensitivity, image resolution, and data processing. Modern technology enhances the value and accuracy of SPECT as a diagnostic tool. For instance, Siemens Healthineers received FDA certification in April 2023 for their SPECT-CT system, the Biograph mCT Flow, which is intended for cardiac perfusion imaging.
By type, the Tc-99m segment accounted for the highest revenue-grossing segment in the global single-photon emission computed tomography market in 2023 owing to the widespread availability, cost-effectiveness, and well-established clinical efficacy of technetium-99m radiotracers. For instance, in July 2023, GE Healthcare unveiled the Discovery NM 750i SPECT system, which has better workflow capabilities and improved image reconstruction algorithms. Additionally, the Ga-67 segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for gallium-67 radiotracers in oncology applications. Gallium-67's unique properties, such as its affinity for tumor tissues and inflammatory lesions, make it particularly valuable for diagnostic imaging in cancer patients.
By application, the cardiology segment accounted for the highest revenue-grossing segment in the global single-photon emission computed tomography market in 2023 owing to the increasing prevalence of cardiovascular diseases worldwide and the critical role of SPECT in myocardial perfusion imaging. For instance, in May 2023, Philips Healthcare received CE Mark approval for the Philips Vereos PET/CT system, therefore increasing its SPECT imaging capabilities in Europe. Additionally, the oncology segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing global incidence of cancer and the expanding applications of Single-Photon Emission Computed Tomography (SPECT) in oncological imaging.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global single-photon emission computed tomography market in 2023 owing to the pivotal role of SPECT in routine clinical diagnostics and comprehensive patient care within hospital settings. For instance, Toshiba Corporation and the University of Tokyo Hospital announced a partnership in August 2023 to develop AI-powered image processing tools for SPECT exams. Additionally, the diagnostic imaging centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards outsourcing medical imaging services and the rising demand for specialized diagnostic facilities.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high adoption of advanced medical technologies, and a significant focus on research and development in the field of medical imaging. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing healthcare investments, rising prevalence of chronic diseases, and a growing awareness and adoption of advanced medical imaging technologies, including Single-Photon Emission Computed Tomography (SPECT). For instance, Hitachi, Ltd. introduced the Elucix SPECT system in July 2023, which is intended for effective and superior cardiac and bone imaging.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Single-Photon Emission Computed Tomography Market Report 2023 - 2034
Single-Photon Emission Computed Tomography Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Tc-99m
- Ra-223
- Ga-67
- I-123
- Others
Single-Photon Emission Computed Tomography Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Oncology
- Cardiology
- Neurology
- Others
Single-Photon Emission Computed Tomography Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
Single-Photon Emission Computed Tomography Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Single-Photon Emission Computed Tomography Market: Type Estimates & Trend Analysis
8. Single-Photon Emission Computed Tomography Market: Application Estimates & Trend Analysis
9. Single-Photon Emission Computed Tomography Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Single-Photon Emission Computed Tomography Market
12. Europe Global Single-Photon Emission Computed Tomography Market
13. Asia Pacific Global Single-Photon Emission Computed Tomography Market
14. Latin America Global Single-Photon Emission Computed Tomography Market
15. MEA Global Single-Photon Emission Computed Tomography Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Siemens Healthineers
- GE Healthcare
- Philips Healthcare
- Toshiba Corporation
- Hitachi Ltd.
- Spectrum Dynamics Medical
- DDD-Diagnostic A/S
- Mediso Medical Imaging Systems
- Digirad Corporation
- Gamma Medica Inc.
- Neusoft Corporation
- Canon Medical Systems Corporation
- Positron Corporation
- SurgicEye GmbH
- MILabs B.V.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2024 |
Forecast Period | 2023 - 2034 |
Estimated Market Value ( USD | $ 2.19 Billion |
Forecasted Market Value ( USD | $ 3.14 Billion |
Compound Annual Growth Rate | 3.3% |
Regions Covered | Global |
No. of Companies Mentioned | 15 |